Ziagen clears FDA advisory panel.
Gaylord
G
G
D002986:Clinical Trials as Topic; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D017277:Drug Approval; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D000099227:Abacavir
D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir